Bonnes pratiques d'achat pour les antipaludéens à ... - libdoc.who.int

28. Sixteenth model list of essential medicines, March 2009 (unedited version). Genève, Organisation mondialede la Santé, 2009.http://www.who.int/selection_medicines/committees/expert/17/WEB_unedited_16th_LIST.pdf29. Second model list of essential medicines for children, March 2009 (unedited version). Genève, Organisationmondiale de la Santé, 2009.http://www.who.int/selection_medicines/committees/expert/17/WEB_unedited_2nd_CHILD-REN_LIST.pdf30. Global malaria control and elimination: report of a meeting on containment of artemisinin tolerance, 19January 2008. Genève, Organisation mondiale de la Santé, 2008.http://www.who.int/malaria/docs/drugresistance/Malaria_Artemisinin.pdf31. Kindermans JM et al. Ensuring sustained ACT production and reliable artemisinin supply. MalariaJournal, 2007, 6:125. doi:10.1186/1475-2875-6-125.32. Expert consultation on the procurement and financing of antimalarial drugs, 15–16 September 2003,final meeting. La Banque mondiale, Washington DC, 2003.http://www.who.int/malaria/docs/AntimalarialDrugProcurementFinancing_Draft.pdf33. Malaria case management: operations manual. Genève, Organisation mondiale de la Santé, 2007.34. Malaria booster control program. Procurement and supply management. Toolkit. La Banque mondiale,Washington DC, Procurement Policy and Services Group, 2006.http://siteresources.worldbank.org/INTPROCUREMENT/Resources/Malaria-Toolkit.pdf35. Good manufacturing practices for sterile products. Genève, Organisation mondiale de la Santé. Série deRapports techniques, N° 902 ; annexe 6, 2002.http://whqlibdoc.who.int/trs/who_trs_902.pdf36. Good manufacturing practices (GMP): water for pharmaceutical use. Genève, Organisation mondialede la Santé. Série de Rapports techniques, N° 929 ; annexe 3, 2005.http://whqlibdoc.who.int/trs/WHO_TRS_929_eng.pdf37. Additional guidance for organizations performing in vivo bioequivalence studies. Genève, Organisationmondiale de la Santé. Série de Rapports techniques, N° 937 ; annexe 9, 2006.http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf38. Lignes directrices concernant l’application du Système OMS de certification de la qualité des produitspharmaceutiques entrant dans le commerce international. In : Comité OMS d’experts des spécificationrelatives au préparations pharmaceutiques. Genève, Organisation mondiale de la Santé. Série de Rapportstechniques, N° 863 ; annexe 10, 1996. Disponible à l’adresse :http://www.who.int/medicines/areas/quality_safety/regulation_legislation/certification/en/39. Proposal for improvement of the WHO certification scheme on the quality of pharmaceutical productsmoving in international commerce. Working document. Genève, Organisation mondiale de la Santé,2007 (QAS/07.240).http://www.who.int/medicines/services/expertcommittees/pharmprep/WHOCertificationSchemeImprovement_QAS07_240.pdf40. Caudron JM et al. Substandard medicines in resource-poor settings: a problem that can no longer beignored. Tropical Medicine and International Health, 2008, 13:1062–1072.41. Committee for Medicinal Products for Human Use (CHMP). Article 58 of Regulation (EC) No.726/2004 1. London, European Medicines Agency, 2004.http://www.emea.europa.eu/htms/human/non_eu_epar/background.htm42. Résumés législatifs. Projet de Loi C-9 : Loi modifiant la loi sur les brevets et la loi sur les aliments etdrogues. Bibliothèque du Parlement – Service d’information et de recherche parlementaires, Ottawa.Disponible à l’adresse:http://www2.parl.gc.ca/Sites/LOP/LegislativeSummaries/Bills_ls.asp?lang=F&ls=C9&source=library_prb&Parl=37&Ses=3Bibliographie87